Crinetics Pharmaceuticals Q4 revenue rises

Crinetics Pharmaceuticals

26/02/2026 21:44

Overview

Pharmaceutical company's Q4 net product revenue from PALSONIFY was $5.4 mln

Company reported Q4 net loss of $122.8 mln

EMA adopted positive opinion for PALSONIFY marketing authorization

Outlook

Crinetics expects 2026 GAAP operating expenses between $600 mln and $650 mln

Company anticipates non-GAAP operating expenses of $480 mln to $520 mln in 2026

Crinetics plans to start Phase 2/3 study of atumelnant in first half of 2026

Result Drivers

PALSONIFY LAUNCH - Generated $5.4 mln in net product revenue in Q4 2025 from the U.S. launch of PALSONIFY, with over 200 enrollment forms by end of December

CLINICAL TRIALS - Initiated multiple trials, including Phase 3 trials for paltusotine and atumelnant, reflecting ongoing R&D investments

R&D EXPENSES - Increased R&D expenses due to investments in paltusotine, atumelnant, and other programs

Company press release: ID:nGNX68K5ZW

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$122.82 mln
Q4 Basic EPS
-$1.29
Q4 Operating Expenses
$139.83 mln
Q4 Operating Income
-$133.67 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Crinetics Pharmaceuticals Inc is $88.00, about 102.8% above its February 25 closing price of $43.39

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)